Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas by Hashimoto, Yosuke et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Prognostic significance of fascin expression in advanced colorectal 
cancer: an immunohistochemical study of colorectal adenomas and 
adenocarcinomas
Yosuke Hashimoto1, Marek Skacel2, Ian C Lavery3,5, Abir L Mukherjee4, 
Graham Casey3,4,5 and Josephine C Adams*1,2,5
Address: 1Department of Cell Biology, Lerner Research Institute, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA, 
2Department of Anatomic Pathology, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA, 3Department of Colorectal Surgery, 
The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA, 4Department of Cancer Biology, Lerner Research Institute, The Cleveland 
Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA and 5Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine at 
Case Western Reserve University, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Email: Yosuke Hashimoto - hashimy@ccf.org; Marek Skacel - mskacel@thefreesite.com; Ian C Lavery - laveryi@ccf.org; 
Abir L Mukherjee - abir2002@yahoo.com; Graham Casey - caseyg@ccf.org; Josephine C Adams* - adamsj@ccf.org
* Corresponding author    
Abstract
Background: Fascin is an actin bundling protein with roles in the formation of cell protrusions and motility of
mesenchymal and neuronal cells. Fascin is normally low or absent from epithelia, but is upregulated in several
epithelial neoplasms where it may contribute to an invasive phenotype. Here, we report on the prevalence and
potential clinical significance of fascin expression in relation to the progression of colorectal adenocarcinoma and
to tumor cell proliferation as measured by Ki67 index.
Methods: Conventional tissue sections of 107 colorectal adenomas and 35 adenocarcinomas were analyzed by
immunohistochemistry for fascin and Ki67 expression.
Fascin expression and Ki67 proliferation index were also investigated by use of a tissue microarray containing
cores from a further 158 colorectal adenocarcinomas and 15 adenomas linked to a CCF, IRB-approved database
with a mean of 38 months of clinical follow-up. Survival analysis was carried out by the Kaplan-Meier and Cox
regression methods.
Results: Fascin was not expressed by the normal colonic epithelium. In conventional sections, 16% of adenomas
and 26% of adenocarcinomas showed fascin expression in greater than 10% of the tumor cells. In the clinically-
annotated tumors, fascin immunoreactivity was more common in tumors located in the proximal colon (p =
0.009), but was not associated with age, gender, or TNM stage. Patients with stage III/IV adenocarcinomas (n =
62) with strong fascin immunoreactivity had a worse prognosis than patients with low or absent fascin, (3-year
overall survival of 11% versus 43% for fascin-negative patients; p = 0.023). In adenomas, fascin and Ki67 tended
to be inversely correlated at the cellular level; this trend was less apparent in adenocarcinomas.
Conclusion: Fascin is upregulated in a proportion of adenomas, where its expression is often focal. Strong and
diffuse expression was seen in a subset of advanced colorectal adenocarcinomas that correlated with shorter
survival in stage III and IV patients. Fascin may have prognostic value as an early biomarker for more aggressive
colorectal adenocarcinomas.
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Background
Colorectal carcinoma (CRC) is the third most lethal
malignancy in the United States for both women and
men, with an overall 5-year survival rate of around 60%
[1]. 106,680 cases of colon and 41,930 cases of rectal can-
cer are expected to occur in 2006. It is estimated that
55,170 deaths from CRC will occur in 2006, accounting
for 10% of all cancer deaths [2]. At present, the only cura-
tive treatment is surgical resection: however, it is often
impossible to remove all cancer cells, especially those that
have invaded the surrounding tissues. The penetration of
tumor cells into lymphoid vessels and blood vessels leads
to tumor metastasis and ultimately the tumor becomes
fatal [3]. The current major method for assessing the risk
of metastatic recurrence and need for adjuvant chemo-
therapy is to examine tumor resection specimens for evi-
dence of metastasis to local lymph nodes. However, this
approach may be of limited prognostic value as a sizeable
fraction of colorectal carcinomas have innate resistance to
chemotherapy and 25% to 30% of the patients presenting
with lymph-node negative tumors also develop fatal dis-
ease [4]. Therefore, there is an urgent need for more accu-
rate and informative methods of individual risk
assessment for patients with CRC, some of which might
be based on the molecular properties of the primary
tumor itself [5].
Tumor invasion and metastasis are the result of highly
coordinated processes that involve multiple intracellular
and extracellular factors [6-8]. In part, carcinoma cell
migration is enabled by the altered differentiation status
of the epithelial cells that includes changes in cell-cell and
cell-matrix adhesion properties and in the organization of
the actin cytoskeleton [9-12]. With regard to the composi-
tion of the cytoskeleton of carcinoma cells, the actin-bun-
dling protein, fascin, has become of great interest due to
its functional involvement in cell adhesion and motility
[13,14]. Fascin is expressed in mature dendritic cells, mes-
enchymal cells, endothelial cells and neurons during
development and in the adult [15,16]. It is absent from
most normal epithelia, but is expressed in multiple epi-
thelial neoplasms, including carcinomas of the pancreas,
lung, esophagus, stomach and breast [17-24]. Most strik-
ingly, fascin expression has been associated with a poorer
prognosis in carcinomas of the lung, esophagus, stomach
and breast [19-21,23]. In node-negative, invasive heredi-
tary breast carcinomas, fascin is frequently expressed by
BRCA1-associated tumors [24]. Fascin has also been iden-
tified as a component of a gene signature that correlates
clinically with breast cancer metastasis to the lung [25].
In cell culture, expression of recombinant fascin in fascin-
negative colonic adenocarcinoma cells correlated with
increased proliferation, altered beta1 integrin distribu-
tion, increased invasive capacity and altered differentia-
tion status [26]. Similar findings have been obtained in
other epithelial cells, suggesting that fascin may contrib-
ute to a more aggressive tumor phenotype by facilitating
carcinoma cell migration and invasion [20,27]. However,
with regard to colorectal cancer, an initial study of tumor
specimens examined only 10 cases without regard to
tumor stage or clinical annotation [26]. Thus, the clinical
relevance of fascin expression in CRC remains unclear and
it is also unknown whether fascin plays any role in the
early development of colorectal carcinoma.
Studies of fascin in multiple cell types have established
that its actin-binding properties are regulated by extracel-
lular cues acting both through adhesion receptors and
receptor tyrosine kinases [14,16,28-30]. Furthermore, sev-
eral studies have indicated that fascin expression may be
related to the proliferative status of carcinomas. In mouse
xenografts, cells from fascin-positive human ovarian car-
cinomas were more tumorigenic than fascin-negative
lines [31]. Colonic epithelial cells engineered to over-
express fascin proliferated faster in culture than control
cells [26]. Despite these findings, the relationship
between fascin expression and cell proliferation in human
cancers is currently unclear. In non-small cell lung carci-
noma, highly fascin-positive tumors tended to be highly
proliferative, as established by Ki67 antibody staining.
However, it was also noted that individual Ki67-positive
cells stained less strongly for fascin than surrounding
tumor cells [19]. In gastric carcinoma, the reverse trend
was observed, with a higher Ki67 index in fascin-positive
areas compared to fascin-negative areas [21].
Here, we have examined the clinicopathological signifi-
cance of fascin and Ki67, singly and in combination, in a
series of colorectal tumor specimens. By examining whole
paraffin-embedded sections, we closely reviewed the
localization and topographic relationship of fascin and
Ki67 in colonic adenomas and colorectal adenocarcino-
mas. The potential prognostic significance of fascin
expression was assessed by using clinically-annotated
samples in a CRC tissue microarray of 158 colorectal ade-
nocarcinomas and 15 adenomas. We report that fascin
and Ki67 are most frequently inversely correlated at the
cellular level. Fascin is upregulated at the adenoma stage
and is of potential prognostic significance as a marker of
aggressive colorectal adenocarcinomas.
Methods
Patients and surgical specimens: conventional sections
We studied 142 tumor samples that included 107 adeno-
mas (89 sporadic and 18 from patients with familial ade-
nomatous polyposis (FAP)) and 35 adenocarcinomas
from an unselected series of cases seen at the Cleveland
Clinic between 2004 and 2006. The adenoma samples
were derived from 76 patients, comprising 65 patientsBMC Cancer 2006, 6:241 http://www.biomedcentral.com/1471-2407/6/241
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with sporadic adenomas and 11 FAP patients. Adenomas
with high grade dysplasia were not included in the set and
only moderately- or poorly-differentiated adenocarcino-
mas were collected. 76 of the sporadic adenomas were < 2
cm in diameter and 13 were > 2 cm. 16 of the FAP were <2
cm and 2 were > 2 cm in diameter. One representative sec-
tion of each specimen was selected for study. In adenocar-
cinomas, this represented the portion of deepest extent. In
adenomas, the sections were selected to demonstrate the
entire lesion including the head and stalk of the adenoma,
where available.
Tissue microarrays
A custom built instrument equipped with stainless steel
thin-wall needles (Beecham Instruments, Hackensack,
NJ), was used to take core tissue biopsies from carefully
selected, morphologically representative areas of the orig-
inal paraffin blocks ("donor" blocks) and arrayed into a
new "recipient" paraffin block. The precision digital
device that equips this instrument allows for precise place-
ment and spacing of the tissue cores into the recipient
block. The resulting tissue microarray (TMA) contained a
total of 374 cores, from 14 normal colonic epithelia, 15
adenomas and 158 colorectal adenocarcinomas that were
diagnosed at The Cleveland Clinic between 1993 and
1999. The majority of the adenocarcinomas were moder-
ately-differentiated and six were poorly-differentiated.
Tumors were classified according to standard TNM staging
guidelines [32], and the location of tumors was divided
into two groups, proximal (cecum, ascending colon,
hepatic flexure and transverse colon) and distal (splenic
flexure, descending colon, sigmoid colon and rectum). Of
the 158 adenocarcinomas, 131 samples were available for
scoring after fascin staining; this study group derived from
79 males and 52 females. The median age was 64.5 years
(range 32–95 years). Of the 62 patients with stage III or
stage IV tumors in the dataset, 19 received no adjuvant
treatment, 27 received adjuvant chemotherapy and 16
received combined adjuvant chemotherapy and radio-
therapy. To minimize sampling errors, two separate large
diameter (1.5 mm) tissue cores of each adenocarcinoma
were included in the array, totaling a surface area of 3.5
mm2 per case. Each separate tissue core was assigned a
unique TMA location number which was subsequently
linked to a CCF Institutional Review Board-approved
(IRB-5085) database containing a mean 38 months of
clinical follow-up.
Immunohistochemical staining
Both the conventional paraffin sections and the TMAs
were treated similarly. Immunohistochemistry was car-
ried out using a fully automated Ventana Benchmark sys-
tem (Ventana, Tucson, AZ). Briefly, 4 μm thick unstained
sections were placed onto a electrostatically charged glass
slide and baked to allow for tissue adherence. The glass
slides were pretreated with the recommended pretreat-
ment solution provided by Ventana for tissue deparaffini-
zation and antigen retrieval. After primary antibody
incubation and a secondary biotinylated antibody/
streptavidin amplification step, antigen detection was car-
ried out by peroxidase/3,3'-diaminobenzidine develop-
ment. Primary antibodies used in this study were directed
against fascin (DAKO, clone 55k-2, dilution 1:50) and
Ki67 (Novacastra, clone MM1, dilution 1:5).
Evaluation of immunohistochemical stainings and scoring
A section without the primary antibody was used as a neg-
ative control in each case. A normal tonsil tissue was used
as a positive control to confirm fascin immunoreactivity
in tonsillar dendritic cells in each series of experiments.
Fascin immunoreactivity in each specimen was verified by
the staining of endothelial cells in microvessels. Fascin-
positive adenoma or adenocarcinoma samples were
defined as those showing a cytoplasmic pattern of expres-
sion. For the conventional sections, each section was
recorded on the basis of the area of fascin staining and was
scored on a four point scale: 1), negative; 2), 1% to 10%
positive; 3), 10% to 50% positive, and 4), more than 50%
positive. For the TMA, this standard scoring scheme was
used with minor modifications. Each separate section or
tissue core was recorded on basis of the area and intensity
of the staining and scored on a 0 to 3+ scale, (0, no stain-
ing; 1+, less than 10% of cells moderately to strongly
stained, or a weak reactivity in any % of cells; 2+, 10% to
50% of cells moderately or strongly stained; 3+, more
than 50% of cells with moderate or strong staining), and
the results entered into the research database. In all sam-
ples, Ki67 index was scored according to the percentage of
cells with positive nuclear staining and was divided into
three groups: 1+ (less than 10% of cells with positive
nuclei); 2+ (10% to 50% of cells with positive nuclei), and
3+ (more than 50% of cells with positive nuclei).
All slides were evaluated independently by two investiga-
tors (YH and MS) without any prior knowledge of the
clinical information. When the opinions of the two eval-
uators differed, a consensus agreement was reached by re-
review of the slides and thorough discussion. Where
scores differed between two cores on the TMA, the average
score was taken.
Statistical analysis
The immunohistochemical staining scores for fascin and
Ki67 in relation to clinicopathological factors were ana-
lyzed using chi-squared. The overall survival was defined
as that from the date of the operation to the date of death
due to cancer. The Kaplan-Meier method was used to
determine the probability of survival and the data were
analyzed by the log-rank test. Multivariate analysis was
performed using the Cox regression model to study theBMC Cancer 2006, 6:241 http://www.biomedcentral.com/1471-2407/6/241
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Expression of fascin and Ki67 in normal colonic epithelium, adenomas and adenocarcinomas Figure 1
Expression of fascin and Ki67 in normal colonic epithelium, adenomas and adenocarcinomas. a, b: immunohisto-
chemical staining for fascin and Ki67 in normal colonic epithelium. c-g: fascin staining in sporadic adenoma (c, d, f, g) and FAP 
(e). h-l: fascin and Ki67 staining in a moderately-differentiated adenocarcinoma, (h, k), and a poorly-differentiated adenocarci-
noma, (i, l). j: stromal staining of fascin in a colorectal adenocarcinoma. m-p: representative examples of fascin, (m, o), and Ki67 
staining, (n, p), in continuous sections from a sporadic adenoma, (m, n), and a moderately-differentiated adenocarcinoma, (o, 
p). Arrows in o and p indicates examples of areas where fascin and Ki67 are inversely correlated; arrowheads indicate areas 
where staining is over-lapping.
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effect of different variables on overall survival. The soft-
ware StatView for Windows version 5 (SAS Institute, Cary,
NC) was used for the analysis. A p value of < 0.05 was con-
sidered significant.
Results
Fascin upregulation is an early event detectable in 
adenomas
As previously reported, fascin was not expressed in the
normal epithelium. Dendritic cells in lymphoid tissue
and vascular endothelial cells were positive for fascin and
served as internal positive controls (Fig. 1a). To establish
whether fascin is upregulated in adenomas, staining for
fascin was carried out on whole sections from 107 ade-
noma specimens, representing both FAP and sporadic
cases (Table 1). Of the 89 sporadic adenomas, 19 were fas-
cin-negative. Fifty-four adenomas stained for fascin over
less than 10% of the cells, 12 contained between 10% to
50% of fascin-positive cells, and 4 adenomas contained
over 50% fascin-positive cells (example in Fig. 1c) (Table
1). Of the 18 FAP samples, fascin staining was detected in
less than 10% of the cells in 17 cases and in 10% to 50%
of the cells in one case (Fig. 1e). All the sections that
included both the head and stalk of the adenoma showed
that fascin was expressed most intensely at the base of the
crypts, close to the central, stromal stalk region (Fig. 1c).
Fascin-positive groups of cells were also present on the lat-
eral walls of many crypts. From sections that included
both the central stalk and the edge of the adenoma, these
lateral fascin-positive cells were always found to be
accompanied by basal fascin-positive cells adjacent to the
stalk region (Fig. 1d, example shows a edge region of the
same polyp as shown in 1c). Horizontal sections taken
through the heads of adenomas demonstrated that the
fascin-positive areas were distributed across the whole
adenoma (data not shown). In some cases, from both the
FAP and sporadic adenomas, entire crypts were positive,
yet we also found examples of adenomatous glands that
were partly fascin-positive and partly fascin-negative (Fig.
1f). In sections that captured adenomatous structures
adjacent to the normal crypt epithelium, a distinct bound-
ary between the fascin-positive adenomatous area and the
fascin-negative, normal epithelium was seen (Fig. 1g).
Of 35 colorectal adenocarcinomas examined as conven-
tional sections, 26 showed staining for fascin. In all cases,
the staining was cytoplasmic and in most cases the stain-
ing intensity was somewhat weaker than that of vascular
endothelial cells. The extent of fascin staining in these
adenocarcinomas was variable. Many cases showed a
patchy distribution of fascin (example in 1 h), whereas in
others over than 50% of the cells stained strongly (exam-
ple in 1i). Overall, 26% (9 out of 35) of the adenocarcino-
mas contained more than 10% fascin-positive cells (Table
1).
In some tumor specimens we noticed elevated fascin
staining in the stroma (Fig. 1j). This staining was not
always uniform: in some cases, only some regions of the
stroma were positive. This stromal staining appeared
independent of tumor staining, because examples of fas-
cin-positive stroma were identified in the presence or
absence of fascin staining of the tumor cells (data not
shown).
Fascin expression correlates with a poor prognosis in stage 
III and IV colon adenocarcinoma patients
To determine whether fascin expression correlated with
the clinical course of CRC, we utilized a TMA of colorectal
adenocarcinomas for which clinical annotation was avail-
able through an IRB-approved database. The clinical and
pathological characteristics of the study group represented
the traditional prognostic variables of colorectal adeno-
carcinomas (Table 2). Tumor stages and lymph node
involvement as represented in the study group correlated
well with patient survival (Fig. 2). After staining the 158
adenocarcinomas on the array for fascin, 131 adenocarci-
noma samples were available for scoring: several cores did
not contain proper tissues or were detached during the
staining procedure. Within the set of 131 cases, the prog-
nostic variables were represented as in the original dataset
(Table 2). Of these 131 specimens, 93 tumors (71%) were
negative for fascin and 38 (29%) were positive (Table 3).
Elevated stromal fascin was detected in 62 cases. Tumor
fascin immunoreactivity was seen most commonly in ade-
nocarcinomas from the proximal colon (p = 0.009), but
was not associated with age, gender or TNM stage (Table
3). Elevated stromal fascin staining correlated positively
with male gender (p = 0.045) and was inversely correlated
Table 1: Fascin positivity in adenomas and adenocarcinomas
Fascin-positive cells
0 1–10% 10–50% 50%+
FAP (n = 18)
n5 1 2 1 0
%2 8 6 7 6 0
Sporadic adenoma (n = 89)
n 1 9 5 41 24
% 2 1 6 11 45
Adenocarcinoma (n = 35)
n9 1 7 3 6
%2 6 4 9 9 1 7
Adenocarcinoma (TMA) (n = 131)
n 9 3 1 61 66
% 7 1 1 21 25BMC Cancer 2006, 6:241 http://www.biomedcentral.com/1471-2407/6/241
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with stage (p = 0.01), increasing age (p = 0.035) and
lymph node metastasis (p = 0.03).
To examine whether tumor fascin expression correlated
with patient survival, the fascin-positive cases represented
on the TMA were divided into two groups: fascin low, (0
or 1+, n = 113), or fascin high, (2+ or 3+, n = 18). Whereas
in the complete set of 131 patients there was no signifi-
cant difference in survival between patients with low or
high fascin expression using the Kaplan-Meier method, (p
= 0.226, data not shown), in the 62 patients with stage III
or stage IV tumors the survival of patients with tumors
that stained strongly for fascin was significantly worse
than that of patients with tumors that stained weakly or
were negative for fascin (p = 0.023) (Fig. 3). This correla-
tion was independent of whether the patients had
received adjuvant treatments or not: patients that had
received adjuvant therapies did not have significantly
longer survival times than other patients diagnosed with
stage III or IV tumors and the fascin-high group of patients
included patients both with and without adjuvant therapy
(data not shown). Elevated fascin staining in stromal cells
did not correlate significantly with patient survival (data
not shown).
Cox multivariant analysis demonstrated that lymph node
metastasis (N1, 2) was an independent adverse prognostic
factor; however, fascin (high), age (>65 years), gender
(male) and tumor location (proximal) were not inde-
pendent prognostic factors in the total group of 131
patients with stage I-IV colorectal adenocarcinoma (Table
4). For the stage III and IV patients, tumor fascin appeared
to be an independent adverse prognostic factor (p =
0.039) (Table 4). For stage III and IV patients, all other
variables, (age, gender, lymph node metastasis and proxi-
mal tumor location), were not independent prognostic
factors (Table 4).
Relationship between fascin and Ki67 staining
We evaluated the possible relationship between fascin
and Ki67 staining in normal tissue, adenomas, adenocar-
cinoma sections and the TMA. In all samples, Ki67 stain-
ing was restricted to the nucleus. In the normal tissue,
Ki67-positive cells were most apparent in the epithelium,
concentrated around the base of the crypt. Staining was
only rarely detected in stromal cells (Fig. 1b).
Out of the 131 adenocarcinomas in the TMA, all showed
some level of Ki67 staining (Table 5). A detailed compar-
ison of fascin and Ki67 staining at cellular level was made
using consecutive sections from 51 adenomas and 12 ade-
nocarcinomas. In the adenomatous crypts, Ki67 expres-
sion tended to be highest at the top of each crypt,
relatively low in the central region and intermediate at the
base (data not shown). Using adenoma cases that stained
positively for both fascin and Ki67, we found that the two
markers tended to be inversely correlated. Thus, groups of
cells with a high Ki67 index were negative for fascin and
vice versa (Figure 1m, 1n).
In adenocarcinomas, Ki67 staining was more homoge-
nous, with a large fraction of positive tumor cells. The
tumor areas always contained many more Ki67-positive
cells than the stroma (Fig. 1k, 1l). Close examination of
adenocarcinoma specimens that stained positively for
both fascin and Ki67 revealed that the two markers were
inversely correlated in some areas (example arrowed in
Fig. 1o and 1p, which show high magnification fields
from the adenocarcinoma in Fig. 1h and 1k), yet appeared
to be co-expressed in other areas, even within the same
glandular structure (example indicated by arrowhead in
Fig. 1o and 1p). Elevated fascin staining in stromal cells
did not correlate with Ki67-positive cells (data not
shown).
Ki67 staining did not correlate with gender, lymph node
metastasis or tumor location, but, as expected, a high Ki67
index correlated with TNM stage (Table 5, p = 0.048).
Patients with a high Ki67 index tended to have a poorer
prognosis, however this was not statistically significant (p
= 0.063) (data not shown). No significant clinical correla-
tion was discovered by correlating Ki67 status with fascin
positivity or negativity, either in the whole group of
patients or in the stage III and IV patients.
Table 2: Clinicopathological characteristics of patients in the 
TMA dataset
Variables n = 158 n = 131
Age
<65 yrs 63 51
≥65 yrs 95 80
Gender
Male 92 79
Female 66 52
Stage
I/II 83 69
III/IV 75 62
Lymph node metastasis
Negative 93 78
Positive 65 53
Location
Proximal 43 37
Distal 115 94BMC Cancer 2006, 6:241 http://www.biomedcentral.com/1471-2407/6/241
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Kaplan-Meier survival curves of the TMA study population Figure 2
Kaplan-Meier survival curves of the TMA study population. The traditional clinicopathological prognostic factors for 
colorectal carcinoma, TNM stage, (A), and lymph node metastasis, (B), correlate with survival. Both significant at p < 0.0001.
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Discussion
Our study provides several novel insights into the clinical
relevance of fascin in colorectal adenocarcinoma. Most
significantly, fascin was strongly expressed in similar pro-
portions of adenomas and adenocarcinomas, (16% versus
17% to 26%, respectively), and fascin expression in inva-
sive stage III and IV adenocarcinomas correlated signifi-
cantly with decreased survival. Given the known roles of
fascin in cytoskeletal organization and cell migration,
these findings indicate a potential clinical significance of
fascin as a marker or prospective therapeutic target for the
most aggressive forms of colorectal adenocarcinoma. Our
study also clarifies that fascin protein is upregulated in
precancerous lesions, of both inherited and sporadic ori-
gin. Adenomas are known to be of polyclonal origin
[33,34], and additional experimental research will be
needed to establish whether and how fascin-staining ade-
nomas give rise to strongly fascin-staining carcinomas. If
the two groups are indeed related, fascin could have value
as a novel prognostic marker, for example to identify
those individuals who should receive additional monitor-
ing or treatment after the detection and surgical removal
of an adenoma or invasive adenocarcinoma.
A second novel finding of our study was the highly signif-
icant correlation of strong fascin expression with tumor
location in the proximal colon (Table 3). The proximal
and distal colon have different embryonic origins, distinct
blood supplies and innervation [35,36]. Much evidence
supports the concept that tumors of the proximal colon
have specific clinical and pathological characteristics and
arise through distinct genetic and molecular processes
[35-37]. Eighty-seven percent of sporadic tumors with
microsatellite instability (MIN or MSI tumors) occur in
the proximal colon, whereas tumors with chromosomal
instability (CIN tumors) predominate in the distal colon
[36,37]. It has been suggested that methylating carcino-
gens are responsible for the origin of MIN tumors in the
proximal colon [38]. In general, MIN tumors have a better
prognosis [39]. Differing responses of CIN or MIN tumors
to chemotherapy have been reported [39,40]. However, in
our dataset, those patients with strongly fascin-positive
advanced tumors had poorer survival (Figure 3). From
Kaplan-Meier analyses we found that fascin-high, proxi-
mal tumors did not correlate with reduced survival
(unpublished observation). Fascin-high distal tumors
were not represented in large enough numbers in the cur-
rent dataset to obtain a statistically meaningful compari-
son for this group alone. Studies of a larger dataset that
include assessment of the MIN status of tumors, for exam-
ple by staining for the hMLH1 gene product, [41], will be
needed to pursue this interesting correlation in depth.
Our study also revealed that stromal fascin staining was
elevated in 47% of colorectal adenocarcinomas. This
staining was independent of whether the adenocarcinoma
itself was fascin-positive or -negative and tended to be
strongest in the stroma adjacent to the invading front of
the tumor. We postulate that increased stromal fascin rep-
resents an aspect of the host/tumor interaction. Many
properties of the stroma, including extracellular matrix
Table 3: Relationship between fascin immunoreactivity and 
clinicopathologic characteristics
Variables Fascin
0/1+ 2+ 3+
n = 113 n = 12 n = 6 p
Age 0.393
<65 yrs 44 6 1
≥65 yrs 69 6 5
Gender 0.885
Male 69 7 3
Female 44 5 3
Stage 0.971
I/II 60 6 3
III/IV 53 6 3
Lymph node metastasis 0.881
Negative 68 7 3
Positive 45 5 3
Location 0.009*
Proximal 29 3 5
Distal 84 9 1
High fascin expression correlates with a clinically aggressive  tumor phenotype Figure 3
High fascin expression correlates with a clinically 
aggressive tumor phenotype. The Kaplan-Meier survival 
curves show that stage III and IV patients with highly fascin-
positive adenocarcinomas had decreased survival compared 
to patients with fascin-low or -negative tumors (significant at 
p = 0.023).
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composition, density of immune and fibroblastic cells,
angiogenesis and the production of angiogenic and chem-
oattractant factors, are known to be regulated as a result of
crosstalk between the tumor and its surrounding host tis-
sue [6]. The increased stromal fascin staining could reflect
either a higher density of fascin-positive cells, most likely
fibroblasts, or an increased fascin content per cell. From
the Ki67 staining studies, it was clear that elevated stromal
cell fascin did not correlate with zones of increased stro-
mal cell proliferation. Further studies are needed to exam-
ine whether elevated stromal fascin staining is specific to
colorectal adenocarcinomas or is also associated with car-
cinomas in other tissues.
Previous studies have suggested a possible relationship
between fascin expression and increased proliferation of
epithelial cells. Over-expression of fascin in colonic epi-
thelial or its depletion in esophageal carcinoma cells cor-
related, respectively, with increased or decreased cell
proliferation in culture [26,42]. The most strongly stain-
ing fascin-positive non-small cell lung carcinomas tended
to be the most highly proliferative tumors, but cells high
for Ki67 tended to be low for fascin [19]. However, the
reverse trend was documented in gastric tumors, which
had a higher Ki67 index in fascin-positive areas compared
to fascin-negative areas [21]. Our analysis of colorectal
adenomas and adenocarcinomas established that, in the
adenomas, fascin-positive cells and crypts were clearly less
proliferative than fascin-negative crypts (Fig. 1m, 1n). In
the adenocarcinomas, distinctions between the fascin and
Ki67 staining patterns were less clear-cut, but the overall
trend was for fascin-positive cells to be low or negative for
Ki67 and vice versa. Overall, our results do not support the
hypothesis that up-regulation of fascin correlates posi-
tively with cell proliferation. There is accumulating evi-
dence that migration and proliferation are exclusive
behaviors for carcinoma cells and that migrating cells tend
to be concentrated at the invading edge of tumors [43,44].
Thus, tumors containing a large fraction of fascin-positive
cells might have a high potential for invasive behavior.
Indeed, in breast carcinomas, fascin has been identified as
a component of a gene signature that correlates clinically
with tumor metastasis to the lung [25]. This concept
would be in agreement with the correlation of fascin
Table 5: Relationship between Ki67 immunoreactivity and 
clinicopathologic characteristics
Variables Ki67
1+ 2+ 3+
n = 64 n = 51 n = 16 p
Age 0.314
<65 yrs 23 19 9
≥65 yrs 41 32 7
Gender 0.354
Male 39 28 12
Female 25 23 4
Stage 0.048*
I/II 39 20 10
III/IV 25 31 6
Lymph node metastasis 0.467
negative 41 27 10
positive 23 24 6
Location 0.264
Proximal 15 15 7
Distal 49 36 9
Table 4: Multivariant analysis of the TMA study set
a. Cox's proportional hazard analysis in stage I to IV patients
Variables Risk ratio (95% confidence interval) p
Age (≥65y) 1.618(0.944–2.774) 0.080
Gender (male) 0.615(0.365–1.036) 0.068
Lymph node metastasis (N1,2) 3.952(2.276–6.861) <0.001*
Distant metastasis (M1) 1.720(0.938–3.155) 0.797
Tumor location (distal) 1.039(0.593–1.820) 0.894
Fascin (high) 1.184(0.905–3.676) 0.925
b. Cox's proportional hazard analysis in stage III and IV patients
Age (≥65y) 1.259(0.683–2.318) 0.460
Gender (male) 0.603(0.322–1.129) 0.114
Lymph node metastasis (N1,2) 0.969(0.336–2.791) 0.934
Distant metastasis (M1) 1.245(0.539–2.628) 0.566
Tumor location (distal) 1.464(0.776–2.765) 0.240
Fascin (high) 2.301(1.045–5.068) 0.039*BMC Cancer 2006, 6:241 http://www.biomedcentral.com/1471-2407/6/241
Page 10 of 11
(page number not for citation purposes)
expression with an aggressive subset of advanced colon
adenocarcinomas, as we have established from our TMA
study.
Conclusion
We found that the actin-bundling protein fascin is
expressed in a subset of both adenomas and colorectal
adenocarcinomas. Strong and widespread expression of
fascin is detected in 16% of adenomas and between 17%
to 26% of adenocarcinomas. In 47% of colorectal tumors,
fascin was elevated in the surrounding stroma independ-
ent of fascin expression in the tumor. In adenomas, fascin
and Ki67 tended to be inversely correlated at the cellular
level; this trend was less clear in adenocarcinomas. In
advanced tumors, strong tumor fascin staining correlated
significantly with poor survival. Fascin has known roles in
cell morphology and migration and may represent a
potential novel marker or therapeutic target for the iden-
tification and treatment of patients with aggressive forms
of colorectal adenocarcinoma.
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